Success Metrics

Clinical Success Rate
93.6%

Based on 280 completed trials

Completion Rate
94%(280/299)
Active Trials
140(24%)
Results Posted
10%(29 trials)
Terminated
19(3%)

Phase Distribution

Ph not_applicable
244
42%
Ph phase_3
16
3%
Ph phase_1
10
2%
Ph early_phase_1
2
0%
Ph phase_4
17
3%
Ph phase_2
7
1%

Phase Distribution

12

Early Stage

7

Mid Stage

33

Late Stage

Phase Distribution296 total trials
Early Phase 1First-in-human
2(0.7%)
Phase 1Safety & dosage
10(3.4%)
Phase 2Efficacy & side effects
7(2.4%)
Phase 3Large-scale testing
16(5.4%)
Phase 4Post-market surveillance
17(5.7%)
N/ANon-phased studies
244(82.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.2%

280 of 307 finished

Non-Completion Rate

8.8%

27 ended early

Currently Active

140

trials recruiting

Total Trials

585

all time

Status Distribution
Active(191)
Completed(280)
Terminated(27)
Other(87)

Detailed Status

Completed280
Recruiting132
unknown87
Not yet recruiting49
Terminated19
Active, not recruiting8

Development Timeline

Analytics

Development Status

Total Trials
585
Active
140
Success Rate
93.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (0.7%)
Phase 110 (3.4%)
Phase 27 (2.4%)
Phase 316 (5.4%)
Phase 417 (5.7%)
N/A244 (82.4%)

Trials by Status

unknown8715%
terminated193%
not_yet_recruiting498%
active_not_recruiting81%
withdrawn81%
recruiting13223%
completed28048%
enrolling_by_invitation20%

Recent Activity

Clinical Trials (585)

Showing 20 of 585 trialsScroll for more
NCT04807023

Decompensation of Cirrhosis and Iron Metabolism

Completed
NCT05303129Not Applicable

Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor.

Completed
NCT07573735

Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis

Recruiting
NCT07633613Phase 4

Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy.

Not Yet Recruiting
NCT05074680

COVID-19 Antibody Responses In Cystic Fibrosis

Completed
NCT07624955

Comparison of the BIG Score and the Pediatric Trauma Score

Not Yet Recruiting
NCT07178847Not Applicable

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Recruiting
NCT06851975

Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment

Recruiting
NCT07610980Not Applicable

Optimal Shock Energy for Electrical Cardioversion of Atrial Fibrillation

Not Yet Recruiting
NCT03387865

A Clinico-biological Database of Lung Cancers

Recruiting
NCT03825458

Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure.

Recruiting
NCT02878408Not Applicable

Immuno-Genetic, Inflammation, Retro-Virus, Environment

Recruiting
NCT06549374

Kinetics of INF-γ Production in Intensive Care Patients

Recruiting
NCT06086704Phase 2

Study of 18F-FFNP Breast PET/MRI

Recruiting
NCT07592429Not Applicable

Assessment of Immune Memory - Humoral and Cellular - in mPOX-infected Patients : an Ancillary Study of the ANRS0258s MOSAIC Cohort

Not Yet Recruiting
NCT02735824

Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies

Recruiting
NCT07579507Not Applicable

Heterogeneity of Oral Carcinogenesis: From PrEneoplasia to Invasive Squamous Cell Carcinoma

Not Yet Recruiting
NCT07200739

Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI)

Not Yet Recruiting
NCT06247826Not Applicable

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion

Recruiting
NCT07555600Not Applicable

Enumeration and Functional Analysis of Circulating Tumor Cells for Homologous Recombination: a Prospective Single-center Study on Advanced/Metastatic Solid Tumors

Not Yet Recruiting

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
585